Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Jan 5

Brad Good is a Circle Platinum Squarespace expert and Authorized Trainer who has built on the platform since 2008, with more than 1,900 sites to his name. He makes Language Switch, a multilingual plugin for Squarespace 7.1, and writes the guides on this site.

http://www.bradgood.net

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

89bio Provides Business Update and Outlook for 2023